San Francisco, California 94158


The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.


Inclusion Criteria: - Patients diagnosed or suspected to have an acute demyelinating optic neuritis in at least one eye within 2 weeks from the onset of any visual symptom other than pain - Use of disease modifying therapies is not a contraindication - Use of appropriate contraception during period of trial (women) - Understand and signed informed consent Exclusion Criteria: - Other major ophthalmologic disease / concomitant ophthalmologic disorders (e.g. diabetes, macular degeneration, glaucoma, severe myopia, etc) - Disc hemorrhages in qualifying eye - No light perception in qualifying eye - Simultaneous bilateral optic neuritis - Cotton wool spots in qualifying eye - Macular star in qualifying eye - History of significant cardiac conduction block - History of cancer - Suicidal ideation or behavior in 6 months prior to baseline - Pregnancy, breastfeeding, or planning to become pregnant - Involved with other study protocol simultaneously without prior approval - Concomitant use of any other putative remyelinating therapy as determined by investigator - Serum creatinine > 1.5 mg/dL; aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase > 2 times the upper limit of normal - History of drug or alcohol abuse within the past year - Untreated B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid (MMA) and homocysteine) or untreated hypothyroidism - Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal, or other major diseases that, in the PI's judgment, may affect interpretation of study results or patient safety - History or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study.



Primary Contact:

Principal Investigator
Ari Green, MD, MCR
University of California, San Francisco

Michael Devereux, BS
Phone: 415-353-2707

Backup Contact:


Location Contact:

San Francisco, California 94158
United States

Michael Devereux, BA
Phone: 415-353-2707

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.